Companies › Mylan Pharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MR-130A-01 transdermal system Progestin-only contraceptive patch | – | Phase 3 | Female Contraception | May 2027 |
| MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) Progestin-based ovulation inhibitor | – | Phase 2 | Contraception | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07365904 | MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | Phase 2 | Contraception | Other | Nov 2026 |
| NCT06672016 | MR-130A-01 transdermal system | Phase 3 | Female Contraception | Other | May 2027 |
No annotated target.
–
Good Molecules Sirnaomics Healx Skingenix Huons Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.